BROMONT, Québec--(BUSINESS WIRE)--BIOQuébec welcomes the tabling of the 2022-2025 Quebec Life Sciences Strategy (QLSS) which will support - and above all, foster - the growth of Quebec’s life sciences ecosystem. The second version of the QLSS features three major objectives, five areas of focus, and ten promising measures for the industry.
Read More
GE Healthcare will incorporate Imeka's neuroimaging technology into BrainWave MRI to provide additional insights into central nervous system diseases and disorders
Read More
Bromont (Québec), April 21 2022 — BIOQuébec is pleased to be releasing the results of a study on the integration of Quebec innovations into our healthcare system. It is also suggests courses of action to better support Quebec-based biopharmaceutical innovations during the entire process and strengthen Quebec’s autonomy.
Read More
TORONTO, MONTREAL, VANCOUVER, BC and BOSTON, July 26, 2021 /CNW/ - Lumira Ventures today announced a significant expansion of its capital base to support the founding and building of innovative healthcare companies in Canada and the U.S. The closing of the oversubscribed Lumira Ventures IV at US$220 million represents the largest fund Lumira has raised to date, and the largest institutional life sciences venture capital fund ever raised in Canada. In parallel, Lumira closed a strategic venture fund in partnership with an international pharmaceutical company. Collectively, the new funds represent over US$255 million (C$321 million) of committed capital.
Read More
Génome Québec announced today a total investment of $18.4 million in innovative projects on the environment. The Board of Directors of Genome Canada approved funding for eight Canadian projects under the Genomic Solutions for Natural Resources and the Environment competition with a budget allocation of $58.6 million. Six of the eight projects involve Québec researchers, which means Québec is receiving 31% of the overall budget available nationwide
Read More
Montréal – Québec – July 7 – CQDM is proud to announce an investment of $260,100 in Morphocell Technologies, a Montréal- based early-stage regenerative medicine company focused on the development of stem cell-derived engineered liver tissue to treat liver disease. Founded in 2018 to develop ReLiver®, a highly innovative platform technology which has shown immense promise in animal models to restore liver function, treat complications and accelerate liver regeneration, Morphocell has the potential to revolutionize the treatment of liver failure and save patient lives.
Read More
MONTRÉAL, May 21, 2021 /CNW Telbec/ - The Fonds de solidarité FTQ is investing $3 million in Giiant Pharma, a Montreal-based preclinical biotech firm that today announced the closing of $13.5 million in financing.
Read More
The COVID-19 pandemic has underlined the essential role of the biotechnology sector. Québec has a wealth of talented researchers and entrepreneurs in several specialties, including neurology, oncology, rare diseases and cardiology. And investors in the province believe that the life sciences will play a major economic role in the post-coronavirus era.
Read More
CAMBRIDGE, Mass. & MONTREAL--(BUSINESS WIRE)--Repare Therapeutics Inc. (“Repare”), a precision oncology company pioneering synthetic lethality to develop novel therapeutics that target specific vulnerabilities of tumors in genetically defined patient populations, today announced it has entered into an exclusive, worldwide research collaboration with Bristol Myers Squibb (BMS) (NYSE:BMY).
Read More
Toronto Innovation Acceleration Partners (TIAP), Evotec SE and AmorChem II Fund L.P. (AmorChem) are pleased to announce a $1.75M investment into a drug development project focused on a rare skin disease called Netherton Syndrome, that affects one in 200,000 newborns worldwide.
Read More
Prevtec Microbia launches its third vaccine thanks to the support of its shareholders.
Read More